section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

US Brand Names

Joenja

Action

  • Acts as an inhibitor of phosphatidylinositol 3-kinase-delta, thereby inhibiting the signaling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and dysregulation of B and T cells.
Therapeutic effects:

Classifications

Therapeutic Classification: none assigned

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: Unknown.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 isoenzyme, and minor contribution by the CYP3A5, CYP1A2, and CYP2D6 isoenzymes. Primarily excreted in the feces (67%), with 25.5% excreted in the urine.

Half-Life: 10 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid1 hr12 hr

Patient/Family Teaching

Pronunciation

LEN-i-oh-LIS-ib